ReviewBioMed research international2014
Therapy of Helicobacter pylori: present medley and future prospective.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Network meta-analysis of treatment interventions forFrontiers in pharmacology · 2024Pooled it
- The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial.Journal of translational medicine · 2015Trial
- Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.Global journal of health science · 2014Trial
- Construction and evaluation of aFrontiers in immunology · 2025Article
- The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.Frontiers in pharmacology · 2022Review
- Telephone-Based Reeducation of Drug Administration forGastroenterology research and practice · 2020Article
- Role ofWorld journal of gastroenterology · 2016Review
- Role of concomitant therapy forWorld journal of gastroenterology · 2016Article
- Management of Helicobacter pylori infections.BMC gastroenterology · 2016Article
- Vaccine against Helicobacter pylori: Inevitable approach.World journal of gastroenterology · 2016Review
- Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients".Gastroenterology research and practice · 2016Article
- Helicobacter pylori and Gastric Cancer.Frontiers in medicine · 2016Article
- Audit ofInternational journal of microbiology · 2016Article
- Comment on "Bacteria in Cancer Therapy: Renaissance of an Old Concept".International journal of microbiology · 2016Article
- Why do we still have Helicobacter Pylori in our Stomachs.The Malaysian journal of medical sciences : MJMS · 2015Article
- Furazolidone and Helicobacter pylori Treatment.Middle East journal of digestive diseases · 2015Article
- Comment on "Helicobacter pylori Outer Membrane Protein 18 (Hp1125) Is Involved in Persistent Colonization by Evading Interferon- γ Signaling".BioMed research international · 2015Article
- Helicobacter pylori: A Beneficial Gastric Pathogen?Frontiers in medicine · 2014Review
- The Helicobacter pylori dupA: A Novel Biomarker for Digestive Diseases.Frontiers in medicine · 2014Review
- Helicobacter pylori: Emergence of a Superbug.Frontiers in medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of antimicrobial resistance has warned clinicians to adopt new strategies for dealing with the H. pylori infection. The success of various therapeutic regimens has recently declined to unacceptable levels. To date, first line therapies (including concomitant therapy and hybrid therapy), second line therapies (including bismuth-containing quadruple therapy and levofloxacin-containing therapy), and third line therapy (culture-guided therapy) had been introduced. In the near future, treatment of H. pylori is entering into a completely new resistance era. In this setting, despite the recent progress, we may only be targeting the patients with problematic H. pylori. Local preference for antibiotic selection should be an inevitable article in each therapeutic regimen worldwide. Meanwhile, improving the patients' compliance protocols and observed side effects in suggested therapeutic regimens should be considered cautiously. The new strategies in treatment should be adopted based upon local resistance patterns, which requires physician's resistance about the recommended guidelines. Designing new therapeutic regimen, which contains most effective available antibiotics with less possible side effects and high patient compliance, represents a challenging task in treatment of H. pylori infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.